{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:21:31Z","timestamp":1790767291541,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T00:00:00Z","timestamp":1466726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1038\/leu.2016.176","type":"journal-article","created":{"date-parts":[[2016,7,15]],"date-time":"2016-07-15T09:39:58Z","timestamp":1468575598000},"page":"107-114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":100,"title":["A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)"],"prefix":"10.1038","volume":"31","author":[{"given":"R","family":"H\u00e1jek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K L","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Oriol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M A","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Kasparu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Van Droogenbroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D B","family":"Yehuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Hardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Jenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Calbecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"D\u00e1vid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"de la Rubia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Drach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Gasztonyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"G\u00f3rnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Leleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Munder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Offidani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Rajangam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y-L","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J F","family":"San-Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Ludwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,24]]},"reference":[{"key":"BFleu2016176_CR1","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","volume":"111","author":"SK Kumar","year":"2008","unstructured":"Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516\u20132520.","journal-title":"Blood"},{"key":"BFleu2016176_CR2","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867\u2013874.","journal-title":"Mayo Clin Proc"},{"key":"BFleu2016176_CR3","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/leu.2011.196","volume":"26","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149\u2013157.","journal-title":"Leukemia"},{"key":"BFleu2016176_CR4","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2012.30.15_suppl.8095","volume":"30","author":"BG Durie","year":"2012","unstructured":"Durie BG, Moreau P, Sonneveld P, Morgan GJ, Lahuerta JJ, Beksac M et al. Regional differences in the treatment approaches for relapsed multiple myeloma: an IMF study. J Clin Oncol 2012; 30: 15s (abstract 8095).","journal-title":"J Clin Oncol"},{"key":"BFleu2016176_CR5","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","volume":"110","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007; 110: 3557\u20133560.","journal-title":"Blood"},{"key":"BFleu2016176_CR6","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/sj.leu.2405016","volume":"22","author":"KC Anderson","year":"2008","unstructured":"Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008; 22: 231\u2013239.","journal-title":"Leukemia"},{"key":"BFleu2016176_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.ctrv.2010.08.008","volume":"37","author":"NW van de Donk","year":"2011","unstructured":"van de Donk NW, Lokhorst HM, Dimopoulous M, Cavo M, Morgan G, Einsele H et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37: 266\u2013283.","journal-title":"Cancer Treat Rev"},{"key":"BFleu2016176_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"MA Dimopoulos","year":"2015","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC . Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol 2015; 12: 42\u201354.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFleu2016176_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1586\/14737140.2014.906904","volume":"14","author":"M Offidani","year":"2014","unstructured":"Offidani M, Corvatta L, Caraffa P, Leoni P, Pautasso C, Larocca A et al. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data. Expert Rev Anticancer Ther 2014; 14: 499\u2013510.","journal-title":"Expert Rev Anticancer Ther"},{"key":"BFleu2016176_CR10","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012; 120: 2817\u20132825.","journal-title":"Blood"},{"key":"BFleu2016176_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","volume":"12","author":"S Jagannath","year":"2012","unstructured":"Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T et al. An open-label, single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 310\u2013318.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu2016176_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/j.1365-2141.2012.09232.x","volume":"158","author":"R Vij","year":"2012","unstructured":"Vij R, Siegel DS, Jagannath S, Stewart AK, McDonagh K, Bahlis N et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and\/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012; 158: 739\u2013748.","journal-title":"Br J Haematol"},{"key":"BFleu2016176_CR13","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood 2012; 119: 5661\u20135670.","journal-title":"Blood"},{"key":"BFleu2016176_CR14","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/leu.2013.29","volume":"27","author":"AZ Badros","year":"2013","unstructured":"Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia 2013; 27: 1707\u20131714.","journal-title":"Leukemia"},{"key":"BFleu2016176_CR15","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II trials. Haematologica 2013; 98: 1753\u20131761.","journal-title":"Haematologica"},{"key":"BFleu2016176_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/j.1600-0609.1987.tb00784.x","volume":"39","author":"LJ Brandes","year":"1987","unstructured":"Brandes LJ, Israels LG . Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol 1987; 39: 362\u2013368.","journal-title":"Eur J Haematol"},{"key":"BFleu2016176_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0300-2977(01)00140-1","volume":"59","author":"O de Weerdt","year":"2001","unstructured":"de Weerdt O, van de Donk NW, Veth G, Bloem AC, Hagenbeek A, Lokhorst HM . Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma. Neth J Med 2001; 59: 50\u201356.","journal-title":"Neth J Med"},{"key":"BFleu2016176_CR18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLML.2010.n.005","volume":"10","author":"F Zhou","year":"2010","unstructured":"Zhou F, Guo L, Shi H, Lin C, Hou J . Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010; 10: 51\u201355.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFleu2016176_CR19","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blad\u00e9 J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467\u20131473.","journal-title":"Leukemia"},{"key":"BFleu2016176_CR20","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blad\u00e9","year":"1998","unstructured":"Blad\u00e9 J, Samson D, Reese D, Apperley J, Bj\u00f6rkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115\u20131123.","journal-title":"Br J Haematol"},{"key":"BFleu2016176_CR21","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487\u20132498.","journal-title":"N Engl J Med"},{"key":"BFleu2016176_CR22","unstructured":"NCCNClinical Practice Guidelines in Oncology: Multiple Myeloma version 4.2015. Available at http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf accessed 23 April 2015."},{"key":"BFleu2016176_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 2015; 372: 142\u2013152.","journal-title":"N Engl J Med"},{"key":"BFleu2016176_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 2016; 17: 27\u201338.","journal-title":"Lancet Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016176","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:05:38Z","timestamp":1684433138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,24]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["BFleu2016176"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.176","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,24]]},"assertion":[{"value":"7 January 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr H\u00e1jek reports funding from Celgene, Janssen and Merck outside of the submitted work; Dr Masszi has nothing to disclose; Dr Petrucci reports receiving personal fees from Janssen-Cilag, Celgene, and BMS outside the submitted work; Dr Palumbo reports receiving personal fees from Amgen, Bristol-Myers Squibb, Genmab A\/S, Janssen-Cilag, Millennium Pharmaceuticals, Onyx Pharmaceuticals, Sanofi Aventis, Celgene and Array BioPharma outside the submitted work; Dr Rosi\u00f1ol reports personal fees from Onyx during the conduct of the study, and personal fees from Janssen, and Celgene outside the submitted work; Dr Nagler reports funding from Onyx outside the submitted work; Dr Yong has nothing to disclose; Dr Oriol reports other from Celgene, Jansen and Novartis outside the submitted work; Dr Minarik has nothing to disclose; Dr Pour has nothing to disclose; Dr Dimopoulos reports personal fees from Onyx and Celgene outside the submitted work; Dr Maisnar reports funding from Celgene, Janssen, and Amgen outside the submitted work; Dr Rossi has nothing to disclose; Dr Kasparu has nothing to disclose; Dr Droogenbroeck has nothing to disclose; Dr Ben-Yehuda has nothing to disclose; Dr Hardan has nothing to disclose; Dr Jenner received honoraria from Amgen\/Onyx outside the submitted work; Dr Calbecka has nothing to disclose; Dr David has nothing to disclose; Dr de la Rubia has nothing to disclose; Dr Drach has nothing to disclose; Dr Gasztonyi has nothing to disclose; Dr G\u00f3rnik has nothing to disclose; Dr Leleu reports funding from Celgene, Janssen, Leopharma, Amgen, Novartis, and Sanofi outside the submitted work; Dr Munder has nothing to disclose; Dr Offidani reports other from Celgene, Janssen, Amgen, Novartis, and Mundipharma outside the submitted work; Dr Zojer received honoraria from Janssen-Cilag and Mundipharma; Dr Chang is employed by, and owns stock in, Onyx; Dr Rajangam is employed by, and owns stock in, Onyx; Dr San Miguel reports funding from Millennium, Celgene, Novartis, Onyx, Janssen, BMS, and MSD outside the submitted work; and Dr Ludwig reports grants from Takeda, personal fees from Janssen-Cilag, Celgene, Bristol Meyers, Amgen and Onyx outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}